

Application No. 10/076,071
Amendment dated September 7, 2005
Reply to Office Action mailed April 8, 2005

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-530 (Canceled).

531. (Currently amended) A method of treating an angiogenic disease or condition in an animal comprising administering to the animal an effective amount of a metal-binding peptide which does not have a metal ion bound to it the sequence of the peptide being:

$P_1 - P_2,$

wherein:

P_1 is:

Xaa₁ Xaa₂ His or

Xaa₁ Xaa₂ His Xaa₃,

the P₁ portion of the peptide being linear;

P₂ is (Xaa₄)_n;

Xaa₁ is the N-terminal amino acid of the peptide, the only substituents on the α -amino group of Xaa, are hydrogen has an unsubstituted α -amino group, and Xaa₁ is glycine, alanine, valine, leucine, isoleucine, serine, threonine, aspartic acid, asparagine, glutamic acid, glutamine, lysine, hydroxylysine, histidine, arginine, ornithine, phenylalanine, tyrosine, tryptophan, cysteine, methionine, or α -hydroxymethylserine;

Xaa₂ is glycine, alanine, β -alanine, valine, leucine, isoleucine, serine, threonine, aspartic acid, asparagine, glutamic acid, glutamine, lysine, hydroxylysine, histidine, arginine, ornithine, phenylalanine, tyrosine, tryptophan, cysteine, methionine, or α -hydroxymethylserine;

Xaa₃ is glycine, alanine, valine, lysine, arginine, ornithine, aspartic acid, glutamic acid, asparagine, glutamine or tryptophan;

Xaa₄ is any amino acid; and

n is 0-100;

or a physiologically-acceptable salt thereof.